INCA035784

Phase 1Small molecule

Incyte

INCA035784 is one of 9 small molecule programs targeting Myeloproliferative Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloproliferative NeoplasmsRecruiting

Myeloproliferative NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Myeloproliferative Neoplasms

#DrugCompanyPhaseTrials

Jakafi

Incyte

Phase 2

4 2

Cysteine Hydrochloride

Novartis

Phase 2

1 3

Trexall

Jazz Pharmaceuticals

Phase 2

1 4

Vonjo

SSobi, Inc.

Phase 2

2 5

Talzenna

Pfizer

Phase 1

1 6

Tibsovo

SServier

Phase 1

2 7

INCA033989

Incyte

Phase 1

2 8

INCB160058

Incyte

Phase 1

1 9

INCA035784

Incyte

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Myeloproliferative Neoplasms

NCT07008118

Clinical

Trials by Indication[1]

Myeloproliferative Neoplasms1 trial

A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Recruiting· Incyte logo

Incyte·Phase 1·NCT07008118·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INCA035784. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCA035784 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCA035784. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Incyte

INCA035784

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Myeloproliferative Neoplasms1 trial

References

Drug Info

Quick Facts

Related News